EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 148 filers reported holding EAGLE PHARMACEUTICALS INC in Q1 2017. The put-call ratio across all filers is 0.35 and the average weighting 0.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $508,000 | -10.2% | 11,435 | 0.0% | 0.02% | +4.3% |
Q1 2022 | $566,000 | -28.1% | 11,435 | -26.0% | 0.02% | -17.9% |
Q4 2021 | $787,000 | -34.7% | 15,455 | -28.5% | 0.03% | -26.3% |
Q3 2021 | $1,206,000 | +14.2% | 21,617 | -12.4% | 0.04% | +52.0% |
Q2 2021 | $1,056,000 | +15.4% | 24,673 | +36.1% | 0.02% | +19.0% |
Q1 2019 | $915,000 | +25.3% | 18,131 | 0.0% | 0.02% | +16.7% |
Q4 2018 | $730,000 | +93.6% | 18,131 | +233.5% | 0.02% | +125.0% |
Q3 2018 | $377,000 | -8.3% | 5,436 | 0.0% | 0.01% | -20.0% |
Q2 2018 | $411,000 | +43.7% | 5,436 | 0.0% | 0.01% | +42.9% |
Q1 2018 | $286,000 | -64.6% | 5,436 | -64.1% | 0.01% | -63.2% |
Q4 2017 | $809,000 | +21.1% | 15,135 | +78.8% | 0.02% | +26.7% |
Q2 2017 | $668,000 | +97.1% | 8,465 | +107.2% | 0.02% | +87.5% |
Q1 2017 | $339,000 | +4.6% | 4,085 | 0.0% | 0.01% | +14.3% |
Q4 2016 | $324,000 | – | 4,085 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 112,666 | $1,777 | 0.65% |
Smith, Graham & Co., Investment Advisors, LP | 273,099 | $4,306,771 | 0.54% |
BRANDES INVESTMENT PARTNERS, LP | 1,134,363 | $17,888,904 | 0.35% |
TANG CAPITAL MANAGEMENT LLC | 118,857 | $1,874,375 | 0.26% |
Virtus Investment Advisers, Inc. | 20,867 | $329,073 | 0.22% |
DENALI ADVISORS LLC | 32,300 | $509,371 | 0.18% |
Nebula Research & Development LLC | 11,473 | $180,929 | 0.10% |
SCOUT INVESTMENTS, INC. | 131,192 | $1,995,430 | 0.05% |
XTX Topco Ltd | 15,050 | $237,339 | 0.04% |
PDT Partners, LLC | 19,745 | $311,379 | 0.04% |